Edit |   |
---|---|
Antigenic Specificity | CD338 (ABCG2), Human |
Clone | REA909 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | allophycocyanin (APC) conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD338 (ABCG2) Antibody, anti-human, APC, REAfinity™. Clone REA909 recognizes the human CD338 antigen, a multi-pass membrane protein which is also known as ATP-binding cassette sub-family G member 2 (ABCG2) or breast cancer resistance protein (BCRP). CD338 is a member of the ATP-binding cassette (ABC) transporter superfamily and known to contribute to multidrug resistance in cancer chemotherapy. It is highly expressed on primitive stem cells as identified by the side-population phenotype, which is characterized by the efflux of chemicals, including the fluorescent dye Hoechst 33342 and Rhodamine 123. Among ABC transporters that are known to cause multidrug resistance, CD338 is particularly interesting for its potential role in protecting cancer stem cells and its complex oligomeric structure. | Additional information: Clone REA909 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | n/a |
Gene, Accession # | Gene ID: 9429 |
Catalog # | 130-115-230 |
Price | $325 |
Order / More Info | CD338 (ABCG2), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Allikmets, R. et al. (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multi drug resistance. Cancer Res. 58 (23): 5337-5339. | Zhou, S. et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7 (9): 1028-1034. | Mo, W. et al. (2012) Human ABCG2: structure, function, and its role in multi drug resistance. Int J Biochem Mol Biol 3 (1): 1-27. |